These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 12679700)

  • 61. Lopinavir/ritonavir vs. indinavir/ritonavir in antiretroviral naive HIV-infected patients: immunovirological outcome and side effects.
    Bongiovanni M; Bini T; Chiesa E; Cicconi P; Adorni F; Monforte d'Arminio A
    Antiviral Res; 2004 Apr; 62(1):53-6. PubMed ID: 15026202
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Impact of drug levels and baseline genotype and phenotype on the virologic response to amprenavir/ritonavir-based salvage regimens.
    Valer L; González de Requena D; de Mendoza C; Martin-Carbonero L; González-Lahoz J; Soriano V
    AIDS Patient Care STDS; 2004 Jan; 18(1):1-6. PubMed ID: 15006188
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Lopinavir/ritonavir: appraisal of its use in HIV therapy.
    von Hentig N
    Drugs Today (Barc); 2007 Apr; 43(4):221-47. PubMed ID: 17460785
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial.
    Cohen C; Nieto-Cisneros L; Zala C; Fessel WJ; Gonzalez-Garcia J; Gladysz A; McGovern R; Adler E; McLaren C;
    Curr Med Res Opin; 2005 Oct; 21(10):1683-92. PubMed ID: 16238909
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Darunavir in treatment-naïve patients. The ARTEMIS study].
    Estrada V; Fuster M
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 10():10-3. PubMed ID: 19195454
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates.
    Mo H; King MS; King K; Molla A; Brun S; Kempf DJ
    J Virol; 2005 Mar; 79(6):3329-38. PubMed ID: 15731227
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Early initiation of lopinavir/ritonavir in infants less than 6 weeks of age: pharmacokinetics and 24-week safety and efficacy.
    Chadwick EG; Pinto J; Yogev R; Alvero CG; Hughes MD; Palumbo P; Robbins B; Hazra R; Serchuck L; Heckman BE; Purdue L; Browning R; Luzuriaga K; Rodman J; Capparelli E;
    Pediatr Infect Dis J; 2009 Mar; 28(3):215-9. PubMed ID: 19209098
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Long-term safety and effectiveness of lopinavir/ritonavir in antiretroviral-experienced HIV-1-infected children.
    Rudin C; Wolbers M; Nadal D; Rickenbach M; Bucher HC; ;
    Arch Dis Child; 2010 Jun; 95(6):478-81. PubMed ID: 20501542
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Lopinavir.
    Hurst M; Faulds D
    Drugs; 2000 Dec; 60(6):1371-9; discussion 1380-1. PubMed ID: 11152017
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Safety and efficacy of a double-boosted protease inhibitor combination, saquinavir and lopinavir/ritonavir, in pretreated children at 96 weeks.
    Bunupuradah T; van der Lugt J; Kosalaraksa P; Engchanil C; Boonrak P; Puthanakit T; Mengthaisong T; Mahanontharit A; Lumbiganon P; Tompkins E; Burger D; Ruxrungtham K; Ananworanich J;
    Antivir Ther; 2009; 14(2):241-8. PubMed ID: 19430099
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV.
    Collier AC; Tierney C; Downey GF; Eshleman SH; Kashuba A; Klingman K; Vergis EN; Pakes GE; Rooney JF; Rinehart A; Mellors JW;
    HIV Clin Trials; 2008; 9(2):91-102. PubMed ID: 18474494
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The NIQ of lopinavir is predictive of a 48-week virological response in highly treatment-experienced HIV-1-infected subjects treated with a lopinavir/ritonavir-containing regimen.
    Castagna A; Gianotti N; Galli L; Danise A; Hasson H; Boeri E; Hoetelmans R; Nauwelaers D; Lazzarin A
    Antivir Ther; 2004 Aug; 9(4):537-43. PubMed ID: 15456085
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Resistance to amprenavir before and after treatment with lopinavir/ritonavir in highly protease inhibitor-experienced HIV patients.
    Hasson H; Gianotti N; Danise A; Seminari E; Boeri E; Nozza S; Castagna A; Lazzarin A
    AIDS; 2004 Jan; 18(1):123-7. PubMed ID: 15090838
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial.
    Eron J; Yeni P; Gathe J; Estrada V; DeJesus E; Staszewski S; Lackey P; Katlama C; Young B; Yau L; Sutherland-Phillips D; Wannamaker P; Vavro C; Patel L; Yeo J; Shaefer M;
    Lancet; 2006 Aug; 368(9534):476-82. PubMed ID: 16890834
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice.
    Prosperi MC; Zazzi M; Punzi G; Monno L; Colao G; Corsi P; Di Giambenedetto S; Meini G; Ghisetti V; Bonora S; Pecorari M; Gismondo MR; Bagnarelli P; Carli T; De Luca A;
    J Med Virol; 2010 Dec; 82(12):1996-2003. PubMed ID: 20981785
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.
    Kempf DJ; King MS; Bernstein B; Cernohous P; Bauer E; Moseley J; Gu K; Hsu A; Brun S; Sun E
    J Infect Dis; 2004 Jan; 189(1):51-60. PubMed ID: 14702153
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Predictive factors of virologic success in HIV-1-infected children treated with lopinavir/ritonavir.
    Delaugerre C; Teglas JP; Treluyer JM; Vaz P; Jullien V; Veber F; Rouzioux C; Chaix ML; Blanche S
    J Acquir Immune Defic Syndr; 2004 Oct; 37(2):1269-75. PubMed ID: 15385734
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Antiretroviral activity and safety of lopinavir/ritonavir in protease inhibitor-experienced HIV-infected children with severe-moderate immunodeficiency.
    Resino S; Bellón JM; Muñoz-Fernández MA;
    J Antimicrob Chemother; 2006 Mar; 57(3):579-82. PubMed ID: 16446377
    [No Abstract]   [Full Text] [Related]  

  • 79. Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study).
    Breilh D; Pellegrin I; Rouzés A; Berthoin K; Xuereb F; Budzinski H; Munck M; Fleury HJ; Saux MC; Pellegrin JL
    AIDS; 2004 Jun; 18(9):1305-10. PubMed ID: 15362663
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial.
    Dragsted UB; Gerstoft J; Youle M; Fox Z; Losso M; Benetucci J; Jayaweera DT; Rieger A; Bruun JN; Castagna A; Gazzard B; Walmsley S; Hill A; Lundgren JD;
    Antivir Ther; 2005; 10(6):735-43. PubMed ID: 16218173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.